Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the ...
As a rise in new mpox cases garners international attention, Danish drugmaker Bavarian Nordic is stacking up orders for its Jynneos vaccine and simultaneously seeing its share price jump. This week, ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION The ...
Bavarian Nordic's COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push
Bavarian Nordic has evidence its COVID-19 vaccine may hold up against omicron. With a midphase trial finding antibody titers were boosted to levels associated with a high level of protection, the ...
Bavarian Nordic’s repeatedly delayed phase 3 cancer vaccine trial has come crashing to a halt. The data monitoring committee ended the six-year odyssey after ruling it would be futile to keep treating ...
LONDON, Aug 20 (Reuters) - Danish biotech firm Bavarian Nordic (BAVA.CO), opens new tab could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks ...
U.S. News Insider Tip: If your Munich visit coincides with the opera’s annual summer festival and you’d like to attend a free live broadcast from the National Theatre/open-air concert at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback